Michal Bar-Natan Zommer, MD
Hematology-Oncology, Cancer (Oncology)
Michal Bar-Natan, MD, is Assistant Professor of Medicine (Hematology and Medical Oncology). Her focus is on translational research in malignant hematology, particularly myeloid malignancies and acute lymphoblastic leukemia, and the development of investigator-initiated clinical trials in patients with these conditions. As a member of the Myeloproliferative Neoplasms (MPN) program and Adult Leukemia program and a leader of the Acute Lymphoblastic Leukemia program, Dr. Bar-Natan provides care for patients with MPN, acute leukemia, and other hematological malignancies at The Ruttenberg Treatment Center. She leads early phase clinical trials implementing new therapeutic approaches, such as immunotherapies and combination therapies, and serves as a co-investigator on many other clinical trials with the goal of improving the outcome of patients with MPN and acute leukemia.
In addition to her clinical fellowship training, Dr. Bar-Natan completed a research fellowship at Dana Farber Cancer Institute and Brigham and Women’s Hospital, with a focus on the role that signal transducer and activator of transcription (STAT) proteins play in the development and treatment of myeloproliferative neoplasms and leukemias. She completed a second research fellowship at Beth Israel Deaconess Medical Center, with a focus on the effect of MUC1 oncoprotein signaling on the biology and immunity of acute myeloid leukemia and multiple myeloma. Dr. Bar-Natan has authored numerous publications, as well as a book chapter on immunotherapeutic strategies in multiple myeloma.
- The Mount Sinai Hospital